Effect of Dexmedetomidine on Pulmonary Artery Pressure: A Systematic Review
-
Afsaneh Hashemidoust
,
Mahmoudreza Moharreri
,
Pouria Namaei
,
Alireza Shariafian Attar
,
Ali Moradi
Abstract
Background: Dexmedetomidine, a selective α2-adrenergic receptor agonist, is widely used for sedation and analgesia in critically ill pediatric patients. Its dose-dependent modulation of pre- and postsynaptic receptors induces sympatholysis and vascular effects. While systemic hemodynamic impacts are well-documented, its influence on pulmonary artery pressure (PAP) remains underexplored. This systematic review evaluates dexmedetomidine’s effects on PAP.
Methods: This systematic review analyzes studies from databases including SID, IranMedex, Magiran, Google Scholar, Cochrane, Scopus, and Web of Science (2005–2024). Keywords such as “dexmedetomidine,” “pulmonary artery pressure,” and “pulmonary effects” identified cross-sectional studies assessing PAP changes. Fifteen high-quality articles met inclusion criteria.
Results: Dexmedetomidine’s effects on PAP seem inconsistent. Animal studies have reported both increased PAP with intravenous administration and no significant changes. Paradoxically, some models demonstrated PAP reduction in hypertensive states via suppressed vascular contraction. Human studies have observed transient PAP elevation after bolus dosing, though loading doses have shown no sustained pulmonary vascular effects. Preoperative administration reduced pulmonary vascular resistance and mean arterial pressure. Secondary pulmonary outcomes included improved oxygenation and lung mechanics in restrictive lung disease, though benefits were not universal.
Conclusion: Dexmedetomidine exhibits variable PAP modulation, with evidence suggesting transient pressure spikes after bolus doses but neutral or beneficial effects in controlled administrations. Animal-human discrepancies highlight physiological differences, necessitating further clinical research. Beyond hemodynamics, dexmedetomidine may enhance oxygenation and ventilation-perfusion matching while mitigating pulmonary inflammation, though inconsistent oxygenation outcomes underscore context-dependent variability. These findings emphasize cautious dosing in pulmonary hypertension and identify gaps for future human trials to clarify its role in cardiopulmonary management.
[2] Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anaesthesiol. 2011; 28(1):3-6.
[3] Lee S. Dexmedetomidine: present and future directions. Korean J Anesthesiol. 2019;72(4):323-330.
[4] Cai Q, Liu G, Huang L, Guan Y, Wei H, Dou Z, et al. The Role of Dexmedetomidine in Tumor-Progressive Factors in the Perioperative Period and Cancer Recurrence: A Narrative Review. Drug Des Devel Ther. 2022; 16:2161-2175.
[5] Lavon H, Matzner P, Benbenishty A, Sorski L, Rossene E, Haldar R, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018; 120(1):188-196.
[6] Hoeper MM, Ghofrani HA, Grünig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary Hypertension. Dtsch Arztebl Int. 2017; 114(5):73-84.
[7] Gaine S. Pulmonary hypertension. JAMA. 2000; 284(24):3160-8.
[8] Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019; 53(1):1802148.
[9] Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016; 4(4):306-22.
[10] Chikuda M, Sato K. Effects of dexmedetomidine on porcine pulmonary artery vascular smooth muscle. BMC Anesthesiol. 2019; 19(1):176.
[11] Friesen RH, Nichols CS, Twite MD, Cardwell KA, Pan Z, Pietra B, et al. The hemodynamic response to dexmedetomidine loading dose in children with and without pulmonary hypertension. Anesth Analg. 2013; 117(4):953-959.
[12] Jooste EH, Muhly WT, Ibinson JW, Suresh T, Damian D, Phadke A, et al. Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization. Anesth Analg, 2010. 111(6): 1490-6.
[13] Nishibe S, Imanishi H, Mieda T, Tsujita M. The effects of dexmedetomidine administration on the pulmonary artery pressure and the transpulmonary pressure gradient after the bidirectional superior cavopulmonary shunt. Pediatr Cardiol. 2015; 36(1):151-7.
[14] Nong L, Ma J, Zhang G, Deng C, Mao S, Li H, et al. Dexmedetomidine inhibits vasoconstriction via activation of endothelial nitric oxide synthase. Korean J Physiol Pharmacol. 2016; 20(5):441-7
[15] Kästner SB, Kull S, Kutter AP, Boller J, Bettschart-Wolfensberger R, Huhtinen MK. Cardiopulmonary effects of dexmedetomidine in sevoflurane-anesthetized sheep with and without nitric oxide inhalation. Am J Vet Res. 2005; 66(9):1496-502.
[16] Kanchi M, Inderbitzin DT, Ramesh KN, Suresh PV, Mayya SS, Sivanandam S, et al. Effect of dexmedetomidine on pulmonary artery pressure in children with congenital heart disease and pulmonary hypertension. Ann Card Anaesth. 2020;23(4):465-470.
[17] Unal Y, Pampal HK, Arslan M, Demirel CB, Alkan M. The effects of dexmedetomidine on pulmonary artery pressure in experiment. Bratisl Lek Listy. 2014;115(5):272-4.
[18] Yamaguchi Y, Hosokawa S, Haraguchi G, Kajikawa Y, Sakurai M, Ishii T, et al. The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension. J Pharmacol Exp Ther. 2023;385(2):88-94.
[19] Lazol JP, Lichtenstein SE, Jooste EH, Shiderly D, Kudchadker NA, Tatum GH, et al., Effect of dexmedetomidine on pulmonary artery pressure after congenital cardiac surgery: A pilot study. Pediatr Crit Care Med. 2010; 11(5): 589-92.
[20] Kästner SB, Ohlerth S, Pospischil A, Boller J, Huhtinen MK. Dexmedetomidine-induced pulmonary alterations in sheep. Res Vet Sci. 2007; 83(2):217-26.
[21] But AK, Ozgul U, Erdil F, Gulhas N, Toprak HI, Durmus M, et al. The effects of pre-operative dexmedetomidine infusion on hemodynamics in patients with pulmonary hypertension undergoing mitral valve replacement surgery. Acta Anaesthesiol Scand. 2006;50(10):1207-12.
[22] Ghasemzadeh B, Azizi B, Azemati S, Bagherinasab M, et al., The effects of dexmedetomidine prescription in paediatric patients with pulmonary hypertension under congenital heart surgery. Acta Med Iran, 2020. 58(4):171-176.
[23] Zhang J, Zhang W, Zhang B, Zhang H, Ruan X, Meng F. Effects of dexmedetomidine on hemodynamics and myocardial injury in patients with pulmonary hypertension undergoing mitral valve replacement. Chinese Journal of Anesthesiology. 2013:537-40.
[24] Abdel-Hamid H, Abdel-Azziz M, Aly Omar A. The effect of perioperative use of dexmedetomidine on pediatric patients with pulmonary hypertension undergoing congenital cardiac surgery. Ain Shams Journal of Anesthesiology. 2017;10(1).
[25] Nair AS. Dexmedetomidine in pulmonary hypertension: A Review. Anaesth Pain & Intensive Care. 2013;17(3):279-81.
[26] Xu Y, Zhang Y, Zhang J, Liang W, Wang Y, Zeng Z, et al. High driving pressure ventilation induces pulmonary hypertension in a rabbit model of acute lung injury. J Intensive Care. 2023; 11(1):42.
[27] Hasanin A, Taha K, Abdelhamid B, Abougabal A, Elsayad M, Refaie A, et al. Evaluation of the effects of dexmedetomidine infusion on oxygenation and lung mechanics in morbidly obese patients with restrictive lung disease. BMC Anesthesiol. 2018;18(1):104.
[28] Lee SH, Kim N, Lee CY, Ban MG, Oh YJ. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: A randomised double-blinded trial. Eur J Anaesthesiol. 2016;33(4):275-82.
[29] Jiang L, Li L, Shen J, Qi Z, Guo L. Effect of dexmedetomidine on lung ischemia‑reperfusion injury. Mol Med Rep. 2014; 9(2):419-26.
[30] Kim S, Park SJ, Nam SB, Song SW, Han Y, Ko S, et al. Pulmonary effects of dexmedetomidine infusion in thoracic aortic surgery under hypothermic circulatory arrest: a randomized placebo-controlled trial. Sci Rep. 2021; 11(1):10975.
[31] Kernan S, Rehman S, Meyer T, Bourbeau J, Caron N, Tobias JD. Effects of dexmedetomidine on oxygenation during one-lung ventilation for thoracic surgery in adults. J Minim Access Surg. 2011; 7(4):227-31.
[32] Das BP, Singh AP, Singh RB. Emergency Corrective Surgery of Congenital Diaphragmatic Hernia With Pulmonary Hypertension: Prolonged Use of Dexmedetomidine as a Pharmacologic Adjunct. Anesth Pain Med. 2016; 6(3):e31880.
[33] Nathan AT, Marino BS, Hanna B, Nicolson SC. Novel use of dexmedetomidine in a patient with pulmonary hypertension. Paediatr Anaesth. 2008;18(8):782-4.
[34] Munro HM, Felix DE, Nykanen DG. Dexmedetomidine/ketamine for diagnostic cardiac catheterization in a child with idiopathic pulmonary hypertension. J Clin Anesth. 2009; 21(6):435-8.
| Files | ||
| Issue | Article in Press |
|
| Section | Review Article(s) | |
| Keywords | ||
| Dexmedetomidine Pulmonary artery pressure Pulmonary function | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
